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hElevated CD8 counts with combination antiretroviral therapy (cART) initiation may be an early warning indicator for future treatment
failure. Thus, we investigated whether elevated CD8 counts were associated with virological failure (VF) in the ﬁrst 4 years of cART in
Asian HIV-infected patients in a multicenter regional cohort.
We included patients from the TREAT Asia HIV Observational Database (TAHOD). Patients were included in the analysis if they
started cART between 1996 and 2013 with at least one CD8 measurement within 6 months prior to cART initiation and at least one
CD8 and viral load (VL) measurement beyond 6 months after starting cART. We deﬁned VF as VL ≥400copies/mL after 6 months on
cART. Elevated CD8 was deﬁned as CD8 ≥1200cells/mL. Time to VF was modeled using Cox regression analysis, stratiﬁed by site.
In total, 2475 patients from 19 sites were included in this analysis, of whom 665 (27%) experienced VF in the ﬁrst 4 years of cART.
The overall rate of VF was 12.95 per 100 person-years. In the multivariate model, the most recent elevated CD8 was signiﬁcantly
associated with a greater hazard of VF (HR=1.35, 95%CI 1.14–1.61; P=0.001). However, the sensitivity analysis showed that time-
lagged CD8 measured at least 6 months prior to our virological endpoint was not statistically signiﬁcant (P=0.420).
This study indicates that the relationship between the most recent CD8 count and VF was possibly due to the CD8 cells reacting to
the increase in VL rather than causing the VL increase itself. However, CD8 levels may be a useful indicator for VF in HIV-infected
patients after starting cART.
Abbreviations: cART = combination antiretroviral therapy, CI = conﬁdence interval, HR = hazard ratio, IQR = interquartile range,
LOCF = last observation carried forward, NNRTI = non-nucleoside reverse transcriptase inhibitor, NRTI = nucleoside reverseditor: Akhilanand Chaurasia.
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Survival in HIV-infected individuals has improved since the
introduction of combination antiretroviral therapy (cART).[1,2]
However, there continue to be individuals for whom cART fails
to suppress HIV to undetectable viral load (VL) levels.[3]
According to previous studies, cumulative rates of virological
failure (VF) after 2 years from initial suppression ranged from
20% to 40%.[4–7] Numerous predictors, such as younger age,
African–American ethnicity, poor adherence to medication,
missed visits, lower baseline CD4 counts, and higher baseline
HIV RNA levels, have been associated with VF.[6–13]
Recently, some studies have reported that elevated total CD8
counts may be a potential predictor of VF.[14,15] Interestingly, a
study reported that initial or serial elevated CD8 counts while on
cART or an increase in CD8 counts from cART initiation may be
early warning indicators of future treatment failure.[15] Also,
because monitoring of CD8 counts with CD4 T cells is done in
most countries, including in resource-limited settings, whether
CD8 counts could be used an alternative marker of VF is
important to know in terms of potential ﬁnancial savings.
However, these issues remain unresolved.
Thus, we investigated whether elevated CD8 counts were
associated with increased risk of VF in the ﬁrst 4 years of cART in
Asian HIV-infected patients.2. Methods
We analyzed data from the Therapeutics, Research, Education
and AIDS Training in Asia (TREAT Asia) HIV Observational
Database (TAHOD).[16] TAHOD is a multicenter, prospective,
observational cohort study that was initiated in 2003 to assess
HIV treatment outcomes in the Asia-Paciﬁc region.[16] Patients
were included in the analysis if they started cART between 1996
and 2013 with at least one CD8 measurement within 6 months
prior to cART initiation and at least one CD8 and VL
measurements beyond 6 months after starting cART. The
analysis dataset included follow-up data collected until Septem-
ber 2013. We deﬁned VF as VL ≥400copies/mL after 6 months
on cART. Elevated CD8 was deﬁned as CD8 ≥1200cells/
mL.[15,17]
Time to VF was modeled using Cox regression analysis,
stratiﬁed by site. The risk analysis period began at 6 months from
the start of cART and was censored at the last available VL test.
CD8 counts while on cART were analyzed as a time-updated
covariate lagged to the next visit. Missing CD8 observations were
ﬁlled in using last observation carried forward methods (LOCF)
for up to 18 months. The covariate was then coded as
“unknown” after 18 months until the next measurement. Other
clinical characteristics adjusted in the model were age, sex, mode
of HIV exposure, pre-cART VL, CD4 and CD8, prior mono or
dual therapy, initial cART regimen, hepatitis B and C coinfection,
CDC disease stage, and prior TB diagnosis. Due to potential
collinearity between CD4 and CD8, we did not include pre-cART
CD4 and pre-cART CD8 variables in the same model. The
regression models were ﬁtted using a backward stepwise selection2process. Variables signiﬁcant in the univariate model at P<0.10
were chosen for inclusion in the multivariate model. Variables
with P<0.05 in the ﬁnal multivariate model were considered
statistically signiﬁcant. Sensitivity analyses were performed by
lagging CD8 counts for 6 months as well as measuring the effects
of the changes in CD8 from pre-cART values on VF.
Ethics approval was obtained from institutional review
boards at each of the participating clinical sites, the data
management and analysis center, and the coordinating center.
All data management and statistical analyses were performed
using SAS software version 9.3 (SAS Institute Inc., Cary, NC)
and STATA software version 12.1 (STATA Corp., College
Station, TX).
3. Results
In total, 2475 patients from 19 sites in China, includingHong Kong
SAR, India, Indonesia, Japan, Malaysia, Philippines, Singapore,
South Korea, Taiwan, Thailand, and Vietnam were included in this
analysis.Of the 2475patients, 665 (27%) experiencedVF in theﬁrst
4 years of cART (Table 1). Most patients were males (78.8%) with
heterosexual HIV exposure (54.9%). More than half (64.2%)
initiated cART with nucleoside reverse transcriptase inhibitors
(NRTIs) and non-NRTI (NNRTI) combinations. The median CD8
count prior to cART initiationwas 752 cells/mL (interquartile range
[IQR] 480–1089). At the time of VF, the mean VL was 82,558
copies/mL and the median was 3500copies/mL (IQR 786–42,100
copies/mL). Additionally, there were 196/665 patients (29%) with
VL 400–1000copies/mL, 209 (31%) with VL 1001–10,000copies/
mL, 160 (24%) with VL 10,001–100,000copies/mL, and 100
(15%) with VL>100,000copies/mL. However, there was no
increasing trend in the proportion of patients with CD8 elevation
across these VL groups (P=0.357).
Table 2 shows the Cox regression analysis for time to ﬁrst VF in
the ﬁrst 4 years on cART. The overall rate of failure was 12.95
per 100 person-years. In the univariate analysis, variables
that were signiﬁcant at P<0.10 were time-updated CD8 counts
(P<0.001), age (P=0.005), mode of HIV exposure (P<0.001),
pre-cART CD4 count (P<0.001), prior mono/dual therapy
(P<0.001), initial cART regimen (P<0.001), CDC disease stage
at cART initiation (P<0.001), and prior tuberculosis diagnosis
(P<0.001). In the ﬁnal multivariate model, factors signiﬁcantly
associated with greater hazards of VF were elevated CD8 of
≥ 1200cells/mL after cART initiation versus CD8<1200cells/mL
(hazard ratio [HR]=1.35, 95% conﬁdence interval [CI]=
1.14–1.61; P=0.001), injecting drug use compared with
heterosexual HIV exposure (HR=1.74, 95% CI=1.19–2.54;
P=0.005), having prior mono/dual therapy compared to
initiating with cART (HR=2.43, 95% CI=2.01–2.95;
P<0.001), and being on a protease inhibitor (PI)-based regimen
(HR=1.37, 95% CI=1.12–1.67; P=0.002) and other treatment
combinations (HR=1.60, 95% CI=1.13–2.27; P=0.008)
compared with NRTI+NNRTI combinations. Variables that
showed a protective effect for VF were older age groups of 31 to
40 years (HR=0.74, 95% CI=0.61–0.90; P=0.002), 41 to
50 years (HR=0.66, 95% CI=0.53–0.83; P<0.001), 51 years
Table 1
Patient characteristics.
Total (N=) No VF (N=) VF (N=)
2475 1810 665
∗
P
Age, y
Median age (IQR) 36 (30–43) 36 (31–43) 35 (29–42)
30 649 (26.2) 450 (24.9) 199 (29.9) 0.059
31-40 1035 (41.8) 765 (42.3) 270 (40.6)
41-50 519 (21.0) 395 (21.8) 124 (18.6)
51+ 272 (11.0) 200 (11.0) 72 (10.8)
Sex
Male 1951 (78.8) 1411 (78.0) 540 (81.2) 0.080
Female 524 (21.2) 399 (22.0) 125 (18.8)
Mode of HIV exposure
Heterosexual contact 1360 (54.9) 980 (54.1) 380 (57.1) 0.119
Homosexual contact 795 (32.1) 605 (33.4) 190 (28.6)
Injecting drug use 109 (4.4) 75 (4.1) 34 (5.1)
Other/unknown 211 (8.5) 150 (8.3) 61 (9.2)
Pre-cART viral load (copies/mL)
Median log10 VL (IQR) 4.88 (4.27–5.38) 4.88 (4.29–5.37) 4.89 (4.20–5.38)
10,000 361 (14.6) 251 (13.9) 110 (16.5) 0.291
10,001–100,000 773 (31.2) 570 (31.5) 203 (30.5)
>100,000 814 (32.9) 580 (32.0) 234 (35.2)
Not tested 527 (21.3) 409 (22.6) 118 (17.7)
Pre-cART CD4 (cells/mL)
Median CD4 (IQR) 144 (44–244) 156 (51–247) 115 (32–222)
50 667 (26.9) 451 (24.9) 216 (32.5) <0.001
51-100 318 (12.8) 222 (12.3) 96 (14.4)
101-200 599 (24.2) 441 (24.4) 158 (23.8)
201+ 889 (35.9) 694 (38.3) 195 (29.3)
Not tested 2 (0.1) 2 (0.1) 0 (0.0)
Pre-cART CD8 (cells/mL)
Median CD8 (IQR) 752 (480–1089) 757 (487–1102) 739 (467–1054)
600 906 (36.6) 658 (36.4) 248 (37.3) 0.617
601-1199 1083 (43.8) 788 (43.5) 295 (44.4)
≥1200 486 (19.6) 364 (20.1) 122 (18.3)
Prior mono/dual therapy
No 2096 (84.7) 1635 (90.3) 461 (69.3) <0.001
Yes 379 (15.3) 175 (9.7) 204 (30.7)
Initial cART regimen
NRTI+NNRTI 1590 (64.2) 1226 (67.7) 364 (54.7) <0.001
NRTI+PI 783 (31.6) 523 (28.9) 260 (39.1)
Other 102 (4.1) 61 (3.4) 41 (6.2)
Hepatitis B coinfection
Negative 1782 (72.0) 1306 (72.2) 476 (71.6) 0.300
Positive 213 (8.6) 149 (8.2) 64 (9.6)
Not tested 480 (19.4) 355 (19.6) 125 (18.8)
Hepatitis C coinfection
Negative 1826 (73.8) 1334 (73.7) 492 (74.0) >0.999
Positive 167 (6.7) 122 (6.7) 45 (6.8)
Not tested 482 (19.5) 354 (19.6) 128 (19.2)
CDC stage
A 1392 (56.2) 1078 (59.6) 314 (47.2) <0.001
B 237 (9.6) 176 (9.7) 61 (9.2)
C 846 (34.2) 556 (30.7) 290 (43.6)
Previous TB diagnosis
No 2183 (88.2) 1625 (89.8) 558 (83.9) <0.001
Yes 292 (11.8) 185 (10.2) 107 (16.1)
cART=combination antiretroviral therapy, CDC= centers for disease control, HIV=human immunodeﬁciency virus, IQR= interquartile range, NNRTI=non-nucleoside reverse transcriptase inhibitor, NRTI=
nucleoside reverse transcriptase inhibitor, PI=protease inhibitor, TB= tuberculosis, VF= virological failure.
∗
P-values are x2 test of proportions excluding “not tested” values.
Ku1 et al. Medicine (2016) 95:32 www.md-journal.comand above (HR=0.71, 95% CI=0.54–0.94; P=0.017),
compared with age  30 years, and pre-cART CD4 counts>
200cells/mL (HR=0.68, 95% CI=0.55–0.83; P<0.001) versus
CD4  50cells/mL.3To determine whether elevated CD8 caused subsequent VF or
whether the association seen in Table 2 was the result of CD8
levels increasing due to VF, we performed a sensitivity analysis by
lagging CD8 counts for 6 months. The lagging meant that VF
Table 2
Time to virological failure.
No. of patients Follow up, y No. of VF Rate (/100 pys) Univariate Multivariate
Total 2475 5134 665 12.95 HR 95% CI P HR 95% CI P
Pre-cART CD8 (cells/mL) 0.898
600 906 1932.61 248 12.83 1
601–1199 1083 2204.13 295 13.38 1.03 (0.87, 1.23) 0.701
≥1200 486 997.24 122 12.23 0.97 (0.78, 1.21) 0.796
CD8 counts after cART initiation
∗
(cells/mL)
<1200 – 3744.41 429 11.46 1 1
≥1200 – 1193.99 189 15.83 1.37 (1.15, 1.63) <0.001 1.35 (1.14, 1.61) 0.001†
Unknown – 195.58 47 24.03
Age, y 0.005 0.001†
30 649 1312 199 15.17 1 1
31–40 1035 2158.71 270 12.51 0.81 (0.67, 0.97) 0.024 0.74 (0.61, 0.90) 0.002†
41–50 519 1099.51 124 11.28 0.70 (0.56, 0.88) 0.002 0.66 (0.53, 0.83) <0.001†
51+ 272 563.61 72 12.77 0.75 (0.57, 0.99) 0.040 0.71 (0.54, 0.94) 0.017†
Sex
Male 1951 4009.45 540 13.47 1 1
Female 524 1124.53 125 11.12 0.97 (0.79, 1.19) 0.763 0.92 (0.74, 1.15) 0.488
Mode of HIV exposure <0.001 0.006†
Heterosexual contact 1360 2884.78 380 13.17 1 1
Homosexual contact 795 1656.65 190 11.47 0.71 (0.58, 0.87) 0.001 0.83 (0.67, 1.03) 0.091
Injecting drug use 109 167.32 34 20.32 1.47 (1.01, 2.15) 0.042 1.74 (1.19, 2.54) 0.005†
Other/unknown 211 425.22 61 14.35 0.90 (0.67, 1.20) 0.476 0.99 (0.74, 1.33) 0.961
Pre-cART viral load (copies/mL) 0.511 0.723
10,000 361 729.83 110 15.07 1 1
10,001–100,000 773 1659.07 203 12.24 0.79 (0.63, 1.00) 0.053 0.92 (0.72, 1.17) 0.497
>100,000 814 1639.52 234 14.27 0.88 (0.70, 1.11) 0.275 0.98 (0.76, 1.26) 0.868
Not tested 527 1105.56 118 10.67
Pre-cART CD4 (cells/mL) <0.001 <0.001†
50 667 1310.91 216 16.48 1 1
51–100 318 663.21 96 14.48 0.89 (0.70, 1.14) 0.353 0.91 (0.71, 1.17) 0.462
101–200 599 1268.87 158 12.45 0.78 (0.63, 0.96) 0.019 0.84 (0.68, 1.03) 0.100
>200 889 1884.67 195 10.35 0.64 (0.52, 0.78) <0.001 0.68 (0.55, 0.83) <0.001†
Not tested 2 6.32 0 0.00
Prior mono/dual therapy
No 2096 4434.6 461 10.40 1 1
Yes 379 699.38 204 29.17 2.7 (2.27, 3.22) <0.001 2.43 (2.01, 2.95) <0.001†
Initial cART Regimen <0.001 0.002†
NRTI+NNRTI 1590 3259.55 364 11.17 1 1
NRTI+PI 783 1676.38 260 15.51 1.85 (1.53, 2.25) <0.001 1.37 (1.12, 1.67) 0.002†
Other 102 198.06 41 20.70 2.33 (1.66, 3.28) <0.001 1.60 (1.13, 2.27) 0.008†
Hepatitis B coinfection
Negative 1782 3693.95 476 12.89 1 1
Positive 213 441.25 64 14.50 1.09 (0.83, 1.42) 0.535 1.06 (0.81, 1.39) 0.657
Not tested 480 998.78 125 12.52
Hepatitis C coinfection
Negative 1826 3846.39 492 12.79 1 1
Positive 167 305.21 45 14.74 1.21 (0.88, 1.65) 0.239 1.11 (0.78, 1.56) 0.567
Not tested 482 982.38 128 13.03
CDC Stage <0.001 0.352
A 1392 2849.29 314 11.02 1 1
B 237 570.27 61 10.70 1.09 (0.81, 1.46) 0.580 0.91 (0.67, 1.22) 0.521
C 846 1714.42 290 16.92 1.49 (1.26, 1.76) <0.001 1.11 (0.90, 1.35) 0.326
Previous TB diagnosis
No 2183 4542.4 558 12.28 1 1
Yes 292 591.58 107 18.09 1.47 (1.18, 1.82) <0.001 1.21 (0.97, 1.52) 0.091
Global P-values for age, pretreatment CD8, CD4, and viral load are tests for trend. Other P-values are tests for heterogeneity excluding not tested values.
Non-signiﬁcant factors were presented in the multivariate model adjusted for signiﬁcant predictors, with the exception of pre-cART CD8 due to potential collinearity with the pre-cART CD4 variable.
cART=combination antiretroviral therapy, CDC=Centers for Disease Control, CI =conﬁdence interval, HR=hazard ratio, NNRTI=non-nucleoside reverse transcriptase inhibitor, NRTI=nucleoside reverse
transcriptase inhibitor, PI =protease inhibitor, pys=person-years, TB= tuberculosis, VF=virological failure.
∗
Time-updated covariate where each patient can contribute follow-up time in more than one category.
† P-values represent signiﬁcant covariates in the ﬁnal model.
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Ku1 et al. Medicine (2016) 95:32 www.md-journal.comcould not be associatedwith CD8measurements taken less than 6
months prior to the failure date, thus minimizing the possibility of
capturing the increase in CD8 as a response to VF. Table 3(i)
shows the univariate and the adjusted HRs for the lagged CD8
variable. There was no evidence to suggest that having an
elevated CD8 count at least 6 months prior was associated with
VF in either the univariate (HR=1.07, 95% CI=0.90–1.28; P=
0.420) or the adjusted (HR=1.08, 95% CI=0.91–1.29; P=
0.389) model. This indicates that the relationship between CD8
and VF observed in Table 2 was possibly due to the CD8 cells
responding to the increase in VL rather than causing the VL
increase itself. When absolute CD8 count was replaced by
changes in CD8 from pre-cART values (Table 3[ii]), the increase
in CD8 was borderline signiﬁcant in the univariate model (HR=
1.18, 95% CI=1.00–1.40; P=0.056), but was not associated
with VF in the adjusted model (HR=1.01, 95% CI=0.84–1.22;
P=0.909).4. Discussion
In this study, we found that the most recent elevated CD8 count
after cARTwas signiﬁcantly associated with VF, but there was no
association between elevated CD8 counts measured at least 6
months prior and the subsequent virological outcome. This
suggests that the CD8 levels may be considered not as a predicting
factor of VF but a potential indicator for VF in HIV-infected
patients after starting cART.
The relationship between CD8 response and HIV outcomes is
not fully understood. CD8 response can be measured through
HIV-speciﬁc CD8, CD8 activation, and total CD8 counts.[15]
Among them, HIV-speciﬁc CD8 have an important role in the
control of viremia,[18] increasing in response to ongoing HIV
replication [19] and have been associated with poor out-
comes.[20,21] Activation of CD8 subsets may accelerate immune
dysfunction. The expression of CD38 on CD8 has been linked to
HIV disease progression.[22–24] One cross-sectional study showed
that elevated levels of CD8 CD38 were found in HIV-infected
patients with VF after cART.[14] However, it lacked sufﬁcient
sensitivity and speciﬁcity to replace viral load testing in assessing
the efﬁcacy of ART.
Additionally, some studies have demonstrated elevation of
total CD8 counts in untreated HIV infection [25–27] and showed
signiﬁcant associations between elevated baseline total CD8
counts and progression to AIDS.[28,29] Moreover, a retrospective
cohort study recently reported that an increase in CD8 counts
from cART initiation was signiﬁcantly associated with treatment
failure.[15] This suggests that elevated CD8 counts after cARTTable 3
Sensitivity analyses: (i) CD8 counts lagged for 6 months, and (ii) CD8
Univariate
HR 95% CI
(i) CD8 counts lagged for 6 months† (cells/mL)
<1200 1
≥1200 1.07 (0.90, 1.28)
(ii) Changes in CD8 from pre-cART values†
Decrease or stay the same 1
Increase 1.18 (1.00, 1.40)
Unknown
cART=combination antiretroviral therapy, HR=hazard ratio, CI= conﬁdence interval.
∗
Adjusted for other signiﬁcant predictors.
† Time-updated covariates.
5may be useful as a predictor of VF. Krantz et al explained these
associations by the adverse effects of a hyperdynamic immune
response or low-level viremia associated with increased risk of
VF.
However, in our study, the relationship between CD8 counts
and VF may be due to the CD8 cells responding to, rather than
causing, the VL increase. Possible explanations for these ﬁndings
include the overstimulation of CD8 immune responses against
increased circulating HIV or subsequent CD8 compensation,
known as “blind T-cell homeostasis,” with decreased CD4 in
VF.[30] Leonard et al[30] hypothesized that in T cell loss, both CD4
and CD8 will be produced until the absolute T-cell count is
normal. This suggests that the selective loss of CD4 will induce
the production of both CD4 and CD8 with the result that T-cell
counts will return to normal, but there would be a persistent CD8
elevation and CD4 decrease.[30]
On the other hand, these ﬁndings suggest that using CD8 levels
may be a potential indicator for VF in HIV-infected patients after
starting cART. If CD8 levels could be used as a marker of VF,
they could supplement more expensive and technologically
complex VL testing. In addition, as current ﬂow cytometer access
is greater in resource-limited settings than PCR, this could
facilitate more active monitoring in patient care settings. Further
studies would be needed to determine the clinical and economic
outcome of using CD8 levels as an indicator for VF after cART.
Also, because another situation to suspect VF is CD4 count drop
or failure to increase, comparing CD4 with CD8 values in terms
of association with VF could be needed.
Our study limitations are primarily related to the potential for
bias in our patient sampling and data. Participating cohort study
sites are primarily tertiary-care referral centers, which could
impact the acuity of patients as well as the level of laboratory
monitoring conducted. In addition, not all TAHOD sites
performed routine CD8 or VL testing, and levels of data
completeness varied by both site and country. Our ﬁndings
should be interpreted in these contexts, and may not necessarily
apply to the broader patient populations in the Asia-Paciﬁc.
Secondly, we deﬁned elevated CD8 as ≥ 1200cells/mL. Although
this value is the upper limit of normal, according to clinical
laboratory reference values, it is based on values from Western
populations.
In conclusion, our study indicates that the observed relation-
ship between CD8 counts and VF in our cohort may have been
due to CD8 cell responses to increases in VL rather than causing
the increases themselves. The potential utility of CD8 levels in
monitoring for VF could make it an adjunct to VL testing in the
future.counts replaced by changes in CD8 from pre-cART values.
Multivariate
∗
P HR 95% CI P
1
0.420 1.08 (0.91, 1.29) 0.389
1
0.056 1.01 (0.84, 1.22) 0.909
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